Showing results (191-200 of 276) with videos related to
Sort By:
Pageof 28
Steroids|April 27, 2001
Synthesis of C-5'-alkyl substituted 17-spirofuran 19-norsteroidsV A Khripach, V N Zhabinskii, D N Tsavlovskii, et al.Cancer Treatment Reviews|July 7, 2015
Rectal and colon cancer: Not just a different anatomic siteK Tamas, A M E Walenkamp, E G E de Vries, et al.Scientific Reports|January 14, 2018
High STAP1 expression in DUX4-rearranged cases is not suitable as therapeutic target in pediatric B-cell precursor acute lymphoblastic leukemiaElisabeth M P Steeghs, Marjolein Bakker, Alex Q Hoogkamer, et al.Journal for Immunotherapy of Cancer|August 3, 2022
Molecular imaging to support cancer immunotherapyPim P van de Donk, Sjoukje F Oosting, Daan G Knapen, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 1, 2021
Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissuesFrans V Suurs, Grit Lorenczewski, Julie M Bailis, et al.Journal of Neuroscience Research|January 10, 2002
Beneficial effect of modified peptide inhibitor of alpha4 integrins on experimental allergic encephalomyelitis in Lewis ratsLuc J W van der Laan, Annette van der Goes, Marca H M Wauben, et al.Frontiers in Oncology|January 3, 2022
Radiolabeled Monoclonal Antibody Against Colony-Stimulating Factor 1 Receptor Specifically Distributes to the Spleen and Liver in Immunocompetent MiceStijn J H Waaijer, Frans V Suurs, Cheei-Sing Hau, et al.European Journal of Cancer (Oxford, England : 1990)|September 17, 2025
Non-inferior outcome of abbreviated R-CHOP in patients with stage I primary testicular lymphomaDiana Al-Sarayfi, Johanna A A Bult, Ruben A L de Groen, et al.Blood Advances|February 22, 2024
Tyrosine kinase inhibitor resistance in de novo BCR::ABL1-positive BCP-ALL beyond kinase domain mutationsInge van Outersterp, Judith M Boer, Cesca van de Ven, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2024
Continuous PEGasparaginase Dosing Reduces Hypersensitivity Reactions in Pediatric ALL: A Dutch Childhood Oncology Group ALL11 Randomized TrialInge M van der Sluis, Leiah J Brigitha, Marta Fiocco, et al.Pageof 28